New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
10:02 EDTGSK, CAT, SPF, LEN, ERIC, ANF, HOV, SWIR, GPC, CGV, TSN, PLXT, FITB, BREOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abercrombie & Fitch (ANF) upgraded to Outperform from Market Perform at BMO Capital... BRE Properties (BRE) upgraded to Neutral from Sell at Goldman... CGG Veritas (CGV) upgraded to Overweight from Neutral at JPMorgan... Caterpillar (CAT) upgraded to Outperform from Market Perform at BMO Capital... Ericsson (ERIC) upgraded to Buy from Hold at Deutsche Bank... Fifth Third Bancorp (FITB) upgraded to Outperform from Market Perform at Wells Fargo... Genuine Parts (GPC) upgraded to Buy from Hold at BB&T... Lennar (LEN) upgraded to Buy from Neutral at Compass Point... PLX Technology (PLXT) upgraded to Buy from Hold at Wunderlich... Sierra Wireless (SWIR) upgraded to Outperform from Sector Perform at RBC Capital... Standard Pacific (SPF) upgraded to Buy from Neutral at Compass Point... Tyson Foods (TSN) upgraded to Buy from Underperform at BofA/Merrill... Hovnanian (HOV) upgraded to Neutral from Sell at Compass Point... GlaxoSmithKline (GSK) upgraded to Overweight from Equal Weight at Barclays... Caterpillar (CAT) upgraded to Buy from Outperform at CLSA.
News For ANF;BRE;CGV;ERIC;FITB;GPC;LEN;PLXT;SWIR;SPF;TSN;HOV;GSK;CAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 22, 2015
15:17 EDTGSKGSK looks to conclude negotiations with U.K. on vaccine cost, Bloomberg says
Subscribe for More Information
March 20, 2015
12:41 EDTGSKOn The Fly: Midday Wrap
Stocks began the day sharply higher and have continued to tack on gains throughout the morning. The market’s move put the Nasdaq back above 5,000 and the S&P above 2,100. The market is undergoing quadruple witching, which occurs 4 times per year and typically is accompanied by high volume and volatility. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet. The Baker Hughes U.S. rig count, which has been closely watched in recent months amid the protracted slide in oil prices, is expected at 1:00 pm EDT. The count of U.S. rigs stood at 1125 at the end of last week. In Europe, reports indicate German Chancellor Angela Merkel said Greece has agreed to send a list of overhauled reforms to European officials within days. COMPANY NEWS: Shares of Nike (NKE) advanced 4% following its Q3 earnings beat. Credit Suisse raised Nike's price target to $106 following the report, saying Nike's underlying futures growth remains in double-digits and preliminary FY16 guidance suggests management has been effective in managing currency headwinds... The shares of Biogen (BIIB) rallied 8% after the company reported results for an early stage study of its Alzheimer's drug, BIIB-037. The company announced that the three milligram, six milligram, and ten milligram dose versions of its Alzheimer's treatment, aducanumab, had reduced the amount of amyloid plaque in the brains of Alzheimer's patients taking the drug by statistically significant amounts compared with those taking placebos. The cognitive decline of patients taking BIIB-037 was also significantly less than that of patients who were taking placebos, the company reported. MAJOR MOVERS: Among the notable gainers was Prothena (PRTA), which surged 30% after announcing results from a Phase 1 single ascending dose study of its potential treatment of Parkinson's disease. Also higher was Darden Restaurants (DRI), which gained 4% after the owner of the Olive Garden and Long Horn restaurant chains reported earnings that beat expectations. Among the noteworthy losers was China's Youku Tudou (YOKU), which dropped 9% and was downgraded to Sell at Deutsche Bank after the company reported mixed Q4 results. Also lower was Theravance (THRX), which fell 7% after the company and partner GlaxoSmithKline (GSK) announced that an FDA advisory committee voted that the efficacy data for their Breo Ellipta inhaler provides substantial evidence of a clinically meaningful benefit in adults, however it voted against approval for the proposed indication in 12-17 year olds. INDEXES: Near midday, the Dow was up 189.04, or 1.05%, to 18,148.07, the Nasdaq was up 40.24, or 0.81%, to 5,032.62, and the S&P 500 was up 19.54, or 0.94%, to 2,108.81.
10:00 EDTERICOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Actuant (ATU) downgraded at Stifel... American Capital Mortgage (MTGE) downgraded to Hold from Buy at Wunderlich... Campus Crest (CCG) downgraded at RBC Capital... Care.com (CRCM) downgraded to Neutral from Overweight at JPMorgan... Electrolux AB (ELUXY) downgraded to Neutral from Overweight at JPMorgan... Ericsson (ERIC) downgraded to Equal Weight from Overweight at Morgan Stanley... Extreme Networks (EXTR) downgraded at Raymond James... PrivateBancorp (PVTB) downgraded to Market Perform from Outperform at BMO Capital... TD Ameritrade (AMTD) downgraded to Neutral from Buy at Goldman... Tableau (DATA) downgraded at Mizuho... Tech Data (TECD) downgraded to Hold from Buy at Needham... Tesoro (TSO) downgraded at Wells Fargo... Ultra Clean (UCTT) downgraded to Hold from Buy at Needham... Vince Holding (VNCE) downgraded to Neutral from Overweight at Piper Jaffray... Youku Tudou (YOKU) downgraded to Sell from Hold at Deutsche Bank.
09:47 EDTGSKGlaxoSmithKline, Theravance launch Revlar Ellipta in Italy
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Revlar Ellipta in Italy following the recent approval by the Italian regulatory authorities in December 2014. Relvar is a fixed dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. The components will be administered using the Ellipta, a dry powder inhaler. In Italy, the product is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product is appropriate; and for the symptomatic treatment of adults with Chronic Obstructive Pulmonary Disease with a FEV1<70% predicted normal post-bronchodilator with an exacerbation history despite regular bronchodilator therapy.
06:24 EDTERICEricsson downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
March 19, 2015
18:14 EDTGSKGlaxoSmithKline, Theravance announce FDA panel outcome on Breo Ellipta
GlaxoSmithKline (GSK) and Theravance (THRX) announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States FDA regarding the supplemental New Drug Application for Breo Ellipta as a once-daily inhaled treatment for asthma in patients aged 12 years and older. The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older (16 for, 4 against). The Committee voted that the efficacy data provides substantial evidence of a clinically meaningful benefit in adults (18 for, 2 against) and that the safety in this population has been adequately demonstrated (17 for, 3 against). The Committee voted against approval for the proposed indication in 12-17 year olds (2 for, 18 against). The Committee voted that the efficacy data was not sufficient to demonstrate the benefit (4 for, 16 against) and the safety (1 for, 19 against) has not been adequately demonstrated in this sub-population. The Committee recommended that a large LABA safety trial with FF/VI should be required in adults (13 yes, 7 no) and in 12-17 year olds (17 yes, 2 no and 1 no-vote), similar to the ongoing LABA safety trials being conducted as an FDA Post-Marketing Requirement by each of the manufacturers of LABA containing asthma treatments. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA. Based on these opinions and the data presented, the FDA will make its final decision on approval, which is expected on April 30.
15:12 EDTGSKFDA panel says Breo lacks efficacy data in children with asthma, Bloomberg says
Subscribe for More Information
13:21 EDTCATCaterpillar heads for test of its 52-week low, levels to watch
Shares were last down over 1.5% to $80.01, off the low of the day at $79.56. At the low of the day, next support is at the 52-week low at $78.19. Resistance is at the high of the day at $80.50.
13:17 EDTCATCaterpillar end market conditions still negative, says Wells Fargo
Subscribe for More Information
11:52 EDTLENLennar says "enthusiastic" about prospects for Rialto
Subscribe for More Information
11:23 EDTLENLennar sees strong top, bottom line growth for 2015
Subscribe for More Information
11:22 EDTLENLennar says still on track to deliver 23,500-24,000 homes for 2015
Still expects apartment unit to be profitable for FY. Says still on track to deliver 23,500-24,000 homes for 2015. Severe weather conditions has delayed some construction activities, will slightly reduce backlog conversion ratio. Still expects gross margins for FY to average 24%, Q4 highest gross margin percent for year. Says increasing goal for financial services for FY due to strong refinance environment, now expects to earn $95M-$100M for FY. Sees FY range of profits for Rialto $30M-$40M for FY, heavily weighted to Q4. Sees FY15 effective tax rate in mid-34% range. Says active community count on track to hit 675 by end of 2015.
11:10 EDTLENLennar says housing market continuing slow, steady recovery
Subscribe for More Information
09:12 EDTCATCaterpillar reports retail machines sales down 11% in three months end February
Subscribe for More Information
08:14 EDTERICWorst case scenario unlikely for Ericsson in Apple lawsuit, says Bernstein
Noting that Apple (AAPL) and Ericsson (ERIC) are involved in patent litigation in which Apple has asked the court to limit Apple's royalty payments to Ericsson to the smallest saleable component containing Ericsson's technology, Bernstein says that Ericsson's IP revenue would be reduced to almost nothing if the court grants Apple's request. However, the firm does not believe that Apple's request has a good legal rationale, and it thinks that the court is "extremely unlikely" to grant it. As a result, the firm is "relaxed" about Ericsson's outlook. It keeps an Outperform rating on the shares.
07:26 EDTGSKFDA to hold a joint advisory committee meeting
The Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee discuss the supplemental New Drug Application (sNDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREO® ELLIPTA®), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older in a meeting being held in Gaithersburg, Maryland on March 19 at 8 am. Webcast Link
07:10 EDTGSKTheravance announces trading in common stock halted as FDA meets on sNDA
Subscribe for More Information
06:03 EDTLENLennar reports Q1 EPS 50c, consensus 45c
Subscribe for More Information
March 18, 2015
15:20 EDTLENNotable companies reporting before tomorrow's open
Subscribe for More Information
13:13 EDTLENLennar March volatility elevated into Q1 and outlook
Lennar March call option implied volatility is at 84, April is at 33, May is at 28; compared to its 26-week average of 31 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on March 19.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use